SCHEMBL500015

SCHEMBL500015

OCc1cc(Cl)ccc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.45
MAPT P10636 3/20 0.45
HIF1A Q16665 3/20 0.45
MEN1 O00255 3/20 0.45
HPGD P15428 3/20 0.45
KMT2A Q03164 3/20 0.45
ALOX15 P16050 2/20 0.45
IDO1 P14902 2/20 0.45
HTT P42858 2/20 0.45
SLC22A1 O15245 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSPD1 P10809 1/20 0.45
HSPA5 P11021 1/20 0.45
ALOX12 P18054 1/20 0.45
CASP1 P29466 1/20 0.45
BLM P54132 1/20 0.45
HSPE1 P61604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylsulfanylmethane SCHEMBL6913535 0.90 SLC6A4 (0.41) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL3657647 0.83 CYP3A4 (0.42) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL30360703 0.83 CYP3A4 (0.42) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL710306 0.82 PYCR1 (0.46) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL15813727 0.82 NOS3 (0.41) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL30749355 0.82 PYCR1 (0.46) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL7024324 0.81 HIF1A (0.54) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL2560634 0.81 NOS3 (0.44) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL924319 0.79 HIF1A (0.39) CYP3A4MAPTHIF1AMEN1HPGD
SCHEMBL29381205 0.79 HIF1A (0.39) CYP3A4MAPTHIF1AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459950-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2025-11-04 US disclosed
US-12440506-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2025-10-14 US disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
WO-2025036241-A1 COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING RIBOPEUTIC INC. (CN) 2025-02-20 WO disclosed
US-20240358728-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, LLC (US) 2024-10-31 US disclosed
CN-118791498-A Tetracyclic compound, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2024-10-18 CN disclosed
US-20240218021-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-07-04 US disclosed
WO-2024105159-A1 LIGANDS OF THE M6A-RNA READERS UNIVERSITY OF ZURICH (CH) 2024-05-23 WO disclosed
CN-114621135-B LPA1 small molecule antagonist 上海拓界生物医药科技有限公司 2024-01-30 CN disclosed
CN-111971288-B Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) 普莱鲁德疗法有限公司 2023-12-01 CN disclosed
US-20060234981-A1 Boron-containing small molecules ANACOR PHARMACEUTICALS (US) 2006-10-19 US disclosed
CN-1829521-A Hydrolysis resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS INC (US) 2006-09-06 CN disclosed
WO-2006089067-A2 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2006-08-24 WO disclosed
EP-1638578-A2 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE Anacor Pharmaceuticals, Inc. (US) 2006-03-29 EP disclosed
WO-2005013892-A9 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS INC (US) 2005-04-14 WO disclosed
US-20050054644-A1 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, LLC 2005-03-10 US disclosed
WO-2005013892-A2 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS, INC. (US) 2005-02-17 WO disclosed
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 WO disclosed
US-5587392-A THERAPY FOR ESTROGEN DEPENDENT DISEASES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1996-12-24 US disclosed
EP-0684235-A1 Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1995-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234981-A1 Boron-containing small molecules ETF1, POLR1C, DPM1 CYP3A4 2875/4885MAPT 1768/4885HIF1A 605/4885
US-12459950-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 CYP3A4 2766/4885MAPT 1314/4885HIF1A 2311/4885
US-20240358728-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, LRBA CYP3A4 4344/4885MAPT 3802/4885HIF1A 488/4885
US-20240218021-A1 CYCLIN INHIBITORS CCNI, CCNC, CDK2 CYP3A4 3220/4885MAPT 3868/4885HIF1A 857/4885
US-12440506-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT1, PRMT6 CYP3A4 2775/4885MAPT 2168/4885HIF1A 2516/4885
US-20050054644-A1 Hydrolytically-resistant boron-containing therapeutics and methods of use BTD, GAA, GBA3 CYP3A4 1885/4885MAPT 3790/4885HIF1A 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.